Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03714880
Other study ID # 1317056
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date April 26, 2019
Est. completion date February 26, 2021

Study information

Verified date June 2022
Source University of California, Davis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators plan to study the role of mifepristone prior to the placement of cervical osmotic dilators to evaluate if the medication helps increase the number of dilators. This may help improve safety of dilation and evacuation (D&E) procedures.


Description:

No clear guideline currently exists for best practices involving cervical preparation for women planning dilation and evacuation at 20 weeks and greater. The investigators plan to perform a pilot, randomized, double-blind, placebo-controlled trial. On day 1, 66 participants will receive mifepristone 200 mg orally or placebo 18-24 hours prior to osmotic dilator (Dilapan-S 4-mm) placement (day 2). On day 3, participants will have a D&E procedure. Enrollees will be 18 weeks 0 days to 23 weeks 6 days gestation on the day of the procedure. The primary objective is to evaluate the role of adjunctive mifepristone the day prior to osmotic dilator placement for dilation and evacuation procedures. The primary outcome will be the number of dilators successfully placed. Investigators will compare the number of dilators placed between study arms stratified by gestational age. Secondary outcomes include cervical dilation at time of procedure, proportion of women requiring mechanical dilation at time of surgery, provider impression on ease of procedure and/or difficulty in dilating the cervix when clinically required, and overall complications. Complications or adverse events include cervical laceration requiring repair, perforations, blood transfusions, ED visits, hospitalizations, infection, additional surgical procedures, or extramural deliveries.


Recruitment information / eligibility

Status Terminated
Enrollment 44
Est. completion date February 26, 2021
Est. primary completion date February 26, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: A. Age =18 years B. Gestational age to be 18 weeks 0 days through 23 weeks 6 days on procedure date C. Signed informed procedure consent for dilation and evacuation D. Willing to sign informed consent and follow study protocol Exclusion Criteria: A. Allergy or known intolerance to mifepristone B. Known contraindication to mifepristone for cervical preparation prior to dilation and evacuation: 1. Chronic adrenal failure or insufficiency 2. Concurrent use of long-term corticosteroid therapy 3. Inherited porphyrias C. Any condition that in the opinion of the investigator could impede study participation or collection of study data

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Mifepristone 200 MG
Ingestion of study medication vs placebo
Placebo Oral Tablet
Ingestion of study medication vs placebo

Locations

Country Name City State
United States UC Davis Department of Obstetrics and Gynecology Sacramento California

Sponsors (2)

Lead Sponsor Collaborator
University of California, Davis Society of Family Planning

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants That Had Placement of Expected Dilators or More The number of expected dilators (Dilapan-S) is calculated based on the gestational age. Four dilators are expected to be placed at 18 weeks 0 days to 19 weeks 6 days gestation. Five dilators are expected to be placed at 20 weeks 0 days to 20 weeks 6 days gestation. Six dilators are expected to be placed at 21 weeks 0 days to 21 weeks 6 days gestation. Seven dilators are expected to be placed at 22 weeks 0 days to 23 weeks 5 days gestation. Therefore, at any given gestational age, if the expected number of dilators (or additional dilators) were placed, the participant was counted as "Yes, participant had placement of expected dilators or more." At time of 1 hour clinic visit (10 minutes)
Secondary Cervical Dilation Measurement of cervical dilation at time of procedure At time of ~1 hour scheduled procedure time (1 minute)
Secondary Number of Participants That Required Mechanical Dilation A count of the number of participants that required of mechanical dilation at time of procedure At time of ~1 hour scheduled procedure time (10 minute)
Secondary Pain Dilator Placement Using Visual Analog Scale Title: Pain at time of dilator placement. Participants mark their associated pain score on a 10-cm visual analog scale at time of dilator placement with anchors of "no pain" at 0 cm and "worst pain in your life" at 10 cm.
Higher scores indicate worse outcome.
At time of 1 hour clinic visit (10 minutes)
Secondary Provider Assessment of Procedure as "Very Easy" or "Easy" Survey providers blinded to study grouping regarding overall ease of procedure based on cervical dilation Identified procedures that were categorized as "Very Easy" or "Easy" (Survey response based on Likert scale: "Very Easy," "Easy," "Moderate," "Difficult," "Very Difficult") At time of ~1 hour scheduled procedure time
Secondary Number of Participants That Experienced Complications Composite of complications including cervical lacerations requiring repair, perforations, blood transfusions, ED visits, hospitalizations, infections, additional surgical procedures, or extramural deliveries At time of ~1 hour scheduled procedure time (0-30 minute)
Secondary Number of Participants That Required Mechanical Dilation Number of participants that required mechanical dilation at time of procedure At time of ~1 hour scheduled procedure time
See also
  Status Clinical Trial Phase
Terminated NCT04063904 - Pilot Study of an Ambulatory Medical Abortion Service at 13-18 Weeks of Gestation in Colombia Phase 4
Completed NCT03400358 - Uterocervical Angle in the Pregnancy Termination of Multiparous Women N/A
Recruiting NCT04501809 - Second Trimester Pregnancy Termination in Women With Previous Caesarean Sections N/A
Recruiting NCT03044093 - Mifepristone and Misoprostol Compared With Misoprostol Alone for Second Trimester Abortion Phase 4
Enrolling by invitation NCT06078501 - MisOpRostol Effect on Second Trimester Abortion Blood Loss Phase 3
Completed NCT04181541 - Midlevel Versus Physician-provided Medical Abortion in the Second Trimester N/A
Completed NCT06164067 - The Role of Cervical Consistency Index and Uterocervical Angles in Medical Termination
Completed NCT02033083 - Laminaria Compared to Dilapan-S for Cervical Preparation Before Dilation and Evacuation at 18-24 Weeks of Gestation N/A
Recruiting NCT06123026 - Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion Phase 4
Completed NCT03407521 - Misoprosotol and Isosorbide Mononitrate for Induction of Second Trimester Abortion Phase 4